An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2018

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2024

Conditions
Multiple Myeloma
Interventions
DRUG

Dexamethasone

Dexamethasone, a corticosteroid, is similar to a natural hormone produced by adrenal glands. It relieves inflammation.

DRUG

Pomalidomide

Pomalidomide which is an immunomodulatory drug. This means that pomalidomide modulates the immune system to help fight diseases.

DRUG

Elotuzumab

Elotuzumab is an antibody, that stimulates the immune system to fight diseases

DRUG

Nivolumab

Nivolumab works by blocking an inhibitory signal within immune cells, potentially allowing the immune system to fight the cancer

Trial Locations (3)

02114

Massachusetts General Hospital, Boston

02115

Beth Israel Deaconess Medical Center, Boston

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT03227432 - An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter